Pudendal Nerve Block for Pain Relief During Episiotomy Repair

November 14, 2026 updated by: Zeenat Usman, Shaheed Zulfiqar Ali Bhutto Medical University

Pudendal Nerve Block for Pain Relief During Episiotomy Repair: A Randomized Controlled Trial

Episiotomy is a surgical cut made in the perineum, the area between the vagina and anus, during vaginal childbirth. Repairing an episiotomy can cause pain, and adequate pain relief is important for maternal comfort during and after delivery.

This study will compare two methods of providing anesthesia during episiotomy repair in women undergoing vaginal delivery with a mediolateral episiotomy at the Department of Maternal and Child Health (MCH), Pakistan Institute of Medical Sciences (PIMS), Islamabad, Pakistan.

A total of 80 eligible women will be enrolled and randomly assigned in equal numbers to two groups. The intervention group will receive a bilateral pudendal nerve block in addition to routine episiotomy repair and standard postpartum pain relief. The control group will receive conventional local anesthetic infiltration around the episiotomy area, along with routine repair and standard postpartum pain relief.

Pain will be assessed using a 100-mm Visual Analogue Scale (VAS), on which 0 represents no pain and 100 represents the worst imaginable pain. Pain will be assessed during episiotomy repair and at 1, 3, and 6 hours after delivery.

The study will also compare the need for additional pain medication, pain during sitting and walking, patient comfort and satisfaction, the duration of episiotomy repair, the need for additional local anesthetic, and complications associated with the procedures.

The aim is to determine whether pudendal nerve block provides better pain relief during episiotomy repair and improves early postpartum comfort compared with conventional local anesthetic infiltration.

Study Overview

Detailed Description

Episiotomy is a surgical incision of the perineum performed during vaginal delivery and may be associated with pain during repair and in the early postpartum period. Conventional local perineal infiltration is commonly used to provide anesthesia during episiotomy repair; however, adequate pain relief may not always be achieved.

The pudendal nerve supplies sensory innervation to the vulva, lower vagina, perineum, and anus. Pudendal nerve block is a regional anesthetic technique that may provide effective analgesia during episiotomy repair. This study will evaluate the effectiveness of pudendal nerve block compared with conventional local perineal infiltration in women undergoing mediolateral episiotomy at the Department of Maternal and Child Health, Pakistan Institute of Medical Sciences (MCH PIMS), Islamabad.

Eligible women aged 18 years or older who undergo vaginal delivery with mediolateral episiotomy will be recruited after eligibility assessment and informed consent. Participants will be randomly allocated to one of two groups. The intervention group will receive bilateral pudendal nerve block using 2% lidocaine, in addition to routine episiotomy repair and standard postpartum analgesia. The control group will receive conventional local perineal infiltration according to the institutional protocol. Both groups will receive routine episiotomy repair and standard postpartum analgesia.

Pain intensity will be assessed using a 100-mm Visual Analogue Scale during episiotomy repair and at 1, 3, and 6 hours postpartum. Additional assessments will include the need for rescue analgesia, pain during sitting and walking, patient-reported comfort and satisfaction, duration of repair, requirement for additional local anesthetic, and the success or failure of the nerve block. Adverse events and complications associated with the procedures will also be documented.

The study aims to determine whether pudendal nerve block improves pain relief during episiotomy repair and early postpartum comfort compared with conventional local perineal infiltration. The findings may contribute to the local evidence base for pain management during episiotomy repair.

Study Type

Interventional

Enrollment (Estimated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Zeenat Usman/Medical officier, MS obstetrics and gyanecology
  • Phone Number: +923315333910
  • Email: usmanbut2@gmail.com

Study Contact Backup

  • Name: Sobia Luqman/Assisstant Professor, FCPS obstetrics and gyane
  • Phone Number: +923348626904
  • Email: sobialuqman8@gmail.com

Study Locations

    • ICT
      • Islamabad, ICT, Pakistan, 04485
        • Department of Maternal and Child Health (MCH), Pakistan Institute of Medical Sciences (PIMS)
        • Contact:
          • Zeenat Usman, MS obstetrics and Gyanecology
          • Phone Number: +923315333910
          • Email: usmanbut2@gmail.com
        • Contact:
        • Principal Investigator:
          • Zeenat Usman, Ms Obsterics and gyanecology
        • Sub-Investigator:
          • Sobia Luqman, FCPS-obstertics and gyanecolog
        • Sub-Investigator:
          • Lubaba Tahir

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Women aged 18 years or older
  • Singleton pregnancy
  • Vaginal delivery at MCH PIMS
  • Requirement for mediolateral episiotomy
  • Clinically uncomplicated episiotomy requiring routine repair
  • Ability to understand the study information and provide written informed consent

Exclusion Criteria:

  • Allergy or contraindication to the proposed local anesthetic
  • Known coagulation disorder or significant bleeding tendency
  • Local infection at the proposed injection site
  • Associated third- or fourth-degree perineal tear
  • Extensive vaginal or cervical laceration requiring additional anesthesia
  • Major postpartum hemorrhage or another major postpartum complication requiring urgent management
  • Chronic pelvic or perineal pain, or regular use of analgesic medication before delivery
  • Inability to understand the pain assessment scale or provide informed consent
  • Failed pudendal nerve block despite appropriate technique

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Pudendal Nerve Block Group

Participants will receive bilateral pudendal nerve block using 2% lidocaine, 2 mL, as specified in the study protocol. The procedure will be performed by an appropriately trained obstetrician or anesthetist using a standardized technique. Routine episiotomy repair and standard postpartum analgesia will also be provided.

Bilateral pudendal nerve block performed using the standardized technique specified in the study protocol, with the local anesthetic described in the protocol (2% lidocaine, 2 mL). The procedure will be performed by an appropriately trained obstetrician or anesthetist, in addition to routine episiotomy repair and standard postpartum analgesia.

Local anesthetic administered for bilateral pudendal nerve block at a dose of 2 mL, as specified in the study protocol.

Active Comparator: Conventional Local Infiltration Group

Participants will receive conventional local perineal infiltration anesthesia according to the standard MCH PIMS episiotomy-repair protocol. Routine episiotomy repair and standard postpartum analgesia will be provided.

Conventional local anesthetic infiltration around the episiotomy site according to the standard MCH PIMS episiotomy-repair protocol. Routine episiotomy repair and standard postpartum analgesia will also be provided.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain intensity during episiotomy repair
Time Frame: During episiotomy repair

Pain intensity will be measured using a 100-mm Visual Analogue Scale (VAS), where 0 represents no pain and 100 mm represents the worst imaginable pain. Pain will be assessed at predefined stages during episiotomy repair, including after anesthesia administration, at commencement of repair, during repair, and at completion of repair.

During episiotomy repair

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postpartum pain intensity
Time Frame: 1, 3, and 6 hours postpartum

pain intensity measured using a 100-mm Visual Analogue Scale (VAS), where 0 represents no pain and 100 represents the worst imaginable pain.

1, 3, and 6 hours postpartum
Requirement for rescue analgesia
Time Frame: First 6 hours postpartum

Proportion of participants requiring additional analgesic medication for inadequate episiotomy-related pain relief.

First 6 hours postpartum
Patient satisfaction with pain management
Time Frame: 1-6 hours postpartum

Patient satisfaction with pain management assessed using a 5-point Likert scale, ranging from very dissatisfied to very satisfied.

1-6 hours postpartum

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 31, 2026

Primary Completion (Estimated)

January 31, 2027

Study Completion (Estimated)

February 15, 2027

Study Registration Dates

First Submitted

October 13, 2026

First Submitted That Met QC Criteria

October 13, 2026

First Posted (Actual)

October 20, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 14, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

De-identified individual participant data collected during this study will not be shared with researchers outside the study team. Study data will be used for the planned analyses and reporting of study findings.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe